The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationBenson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationSoverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Self-citationHasford, J., Baccarani, M., Hoffmann, V., Guilhot, J., Saussele, S., Rosti, G., Guilhot, F., Porkka, K., Ossenkoppele, G., Lindoerfer, D., et al. (2011) · Blood · doi:10.1182/blood-2010-12-319038 · Cited by 500
Self-citationEtienne, G., Guilhot, J., Rea, D., Rigal-Huguet, F., Nicolini, F., Charbonnier, A., Guerci-Bresler, A., Legros, L., Varet, B., Gardembas, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2914 · Cited by 496
Self-citationHughes, T. P., Hochhaus, A., Branford, S., Müller, M. C., Kaeda, J. S., Foroni, L., Druker, B. J., Guilhot, F., Larson, R. A., O'Brien, S. G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273979 · Cited by 489
Self-citationSteegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Self-citationFoà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Eichhorst, B., Hallek, M., & Dreyling, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D.-W., Flinn, I. W., Kurokawa, M., Moiraghi, B., Yu, R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.134 · Cited by 442
Self-citationGambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationChronic myeloid leukemia: mechanisms of blastic transformation
Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41246 · Cited by 397
Self-citationImatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Self-citationKantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., et al. (2011) · Blood · doi:10.1182/blood-2010-03-277152 · Cited by 380
Self-citationAn, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.016 · Cited by 309
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0071 · Cited by 277
Self-citationKalmanti, L., Saussele, S., Lauseker, M., Müller, M. C., Dietz, C. T., Heinrich, L., Hanfstein, B., Proetel, U., Fabarius, A., Krause, S. W., et al. (2015) · Leukemia · doi:10.1038/leu.2015.36 · Cited by 277
Self-citationMechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0047 · Cited by 262
Hughes, T. P., Saglio, G., Kantarjian, H. M., Guilhot, F., Niederwieser, D., Rosti, G., Nakaseko, C., De Souza, C. A., Kalaycio, M. E., Meier, S., et al. (2014) · Blood · doi:10.1182/blood-2013-06-510396 · Cited by 257
Self-citationVardiman, J. W. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.10.009 · Cited by 253
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature · doi:10.1038/nature14119 · Cited by 234
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126
Mughal, T. (2010) · Biologics: Targets & Therapy · doi:10.2147/btt.s5775 · Cited by 53
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia
Han, S. H., Korm, S., Han, Y. G., Choi, S.-Y., Kim, S.-H., Chung, H. J., Park, K., Kim, J.-Y., Myung, K., Lee, J.-Y., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596492 · Cited by 53
Farmer, S., Horváth‐Puhó, E., Vestergaard, H., Hermann, A. P., & Frederiksen, H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12581 · Cited by 45
Berman, E., Jhanwar, S., Hedvat, C., Arcila, M. E., Wahab, O. A., Levine, R., Maloy, M., Ma, W., & Albitar, M. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.006 · Cited by 41
Schwarzbich, M.-A., Gutknecht, M., Salih, J., Salih, H. R., Brossart, P., Rittig, S. M., & Grünebach, F. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1096-1 · Cited by 42
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25
Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0595 · Cited by 23
Schleidgen, S., & Marckmann, G. (2013) · BMC Medical Ethics · doi:10.1186/1472-6939-14-20 · Cited by 15
Itonaga, H., Tsushima, H., Imanishi, D., Hata, T., Doi, Y., Mori, S., Sasaki, D., Hasegawa, H., Matsuo, E., Nakashima, J., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.022 · Cited by 12
Metadata
- Authors
- Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., Mone, M., Gathmann, I., Hughes, T. P., Larson, R. A., & for the IRIS Investigators
- Venue
- Leukemia
- Published
- 2009-03-12
- Volume
- 23
- Issue
- 6
- Pages
- 1054-1061
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2091005492
- Cited by
- 856
- References
- 30
- FWCI
- 61.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.